Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: Visby Medical

The first single-use, highly accurate rapid coronavirus test has received the all-clear from the Food and Drug Administration to be used in a wide variety of settings, per its manufacturer, Visby Medical.

Why it matters: Even with vaccines, widespread coronavirus testing is still essential for safely returning to normal life.

The big picture: Many rapid tests aren't as reliable as gold-standard PCR tests, but PCR tests can take days to process and require expensive equipment.

What they're saying: "This is the first time that anyone has been able to take this gold-standard laboratory equipment…and put it in a [form] that anyone can just carry in their hand," Visby CEO Adam de la Zerda said.

  • “The fact that it's single use means you don’t have to worry about an instrument and you have unlimited testing capacity," he added. Results take only 30 minutes.

State of play: The FDA authorized the PCR test for use in labs and hospitals a few months ago. This week, the agency said the test can be used in places like airports, schools and businesses, as long as they've received a waiver from the FDA requirement that tests be run by a laboratorian.

  • The company is producing tens of thousands of tests a month, but is "anticipating to start scaling to the hundreds of thousands of devices per month, and work our way up from there," de la Zerda said.
  • He said the hope is for the tests to eventually be accessible for at-home use, and beyond that, for the technology to be used for other diseases as well.

Go deeper

Feb 9, 2021 - Health

J&J CEO: Annual COVID-19 vaccine shots may be necessary for a few years

Alex Gorsky. Photo: Lucas Jackson/Reuters/Bloomberg via Getty Images

People might need the coronavirus vaccine annually in years to come, much like the seasonal flu shot, Johnson & Johnson CEO Alex Gorsky told CNBC on Tuesday.

What he's saying: "Unfortunately, as [the virus] spreads it can also mutate," Gorsky said at an event. "Every time it mutates, it’s almost like another click of the dial so to speak where we can see another variant, another mutation that can have an impact on its ability to fend of antibodies or to have a different kind of response not only to a therapeutic but also to a vaccine."

Feb 10, 2021 - Health

FDA grants emergency use authorization for Eli Lilly COVID antibody drug

Photo: Igor Golovniov/SOPA Images/LightRocket via Getty Images

The FDA announced Tuesday it has issued an emergency use authorization for a new combination antibody drug from Eli Lilly that can treat mild to moderate COVID-19.

Why it matters: The treatment contains bamlanivimab and etesevimab which, administered together, can reduce the risk of hospitalizations and death by 70%, per an FDA statement. It can be used on patients at high risk of developing severe illnesses.

Updated 17 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Annelise Capossela/Axios

You’ve caught up. Now what?

Sign up for Mike Allen’s daily Axios AM and PM newsletters to get smarter, faster on the news that matters.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!